Medicare Enrolled

Dr. Peter Legnani, MD

Gastroenterology · New York, NY
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
1150 5TH AVE, New York, NY 10128
2123692490
In practice since 2006 (19 years)
NPI: 1942219548 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Legnani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Legnani? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Legnani

Dr. Peter Legnani is a gastroenterology specialist in New York, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Legnani performed 15,399 Medicare services across 449 unique beneficiaries.

Between the years covered by Open Payments, Dr. Legnani received a total of $24,570 from 46 pharmaceutical and/or device companies across 1517 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Legnani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 1% volume in NY $24,570 industry payments

Medicare Practice Summary

Medicare Utilization ↗
15,399
Medicare services
Top 1% in NY for gastroenterology
449
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~810 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Vedolizumab infusion (Entyvio)
This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams.
14,700 $17 $40
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
166 $76 $375
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
148 $110 $400
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
110 $1 $50
Colonoscopy with biopsy
A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease.
84 $122 $2,050
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
54 $59 $300
Colon polyp removal with endoscopic snare
This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination.
51 $227 $2,100
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
31 $87 $450
Upper GI endoscopy with biopsy
A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities.
27 $90 $1,800
Virtual check-in for established patient
A brief communication service provided by a qualified healthcare professional to an established patient via technology, such as a virtual check-in.
17 $11 $50
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
11 $147 $500
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
96.5% high complexity
0.7% medium
2.8% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$24,570
Total received (2018-2024)
Avg $3,510/year across 7 years
Top 12% in NY for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
1,517
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$24,545 (99.9%)
Other
Charitable contributions, space rental, and other categories
$25 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,181
2023
$4,024
2022
$3,585
2021
$3,456
2020
$2,492
2019
$3,688
2018
$3,144

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$744
Takeda Pharmaceuticals U.S.A., Inc.
$595
Celgene Corporation
$573
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$404
QOL Medical, LLC
$305
PFIZER INC.
$255
Janssen Biotech, Inc.
$249
Daiichi Sankyo Inc.
$174
Merck Sharp & Dohme LLC
$159
Ardelyx, Inc.
$150
Lilly USA, LLC
$111
Phathom Pharmaceuticals, Inc.
$77
Organon Llc
$67
Boehringer Ingelheim Pharmaceuticals, Inc.
$66
VIVUS LLC
$59
Regeneron Healthcare Solutions, Inc.
$58
Sandoz Inc.
$32
Ambu Inc.
$24
Braintree Laboratories, Inc.
$24
AIMMUNE THERAPEUTICS, INC.
$21
RedHill Biopharma Inc.
$19
Celltrion USA Inc.
$17
Top 3 companies account for 45.7% of 2024 payments
All-time payments by company (2018-2024) ›
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$4,148
ABBVIE INC.
$2,325
PFIZER INC.
$2,213
Janssen Biotech, Inc.
$2,201
Celgene Corporation
$2,188
Takeda Pharmaceuticals U.S.A., Inc.
$2,058
QOL Medical, LLC
$1,082
UCB, Inc.
$971
Ferring Pharmaceuticals Inc.
$901
AbbVie Inc.
$894
AbbVie, Inc.
$806
Merck Sharp & Dohme Corporation
$508
Merck Sharp & Dohme LLC
$427
Daiichi Sankyo Inc.
$400
Endo Pharmaceuticals Inc.
$387
Allergan Inc.
$344
Amgen Inc.
$324
Ironwood Pharmaceuticals, Inc
$231
Ardelyx, Inc.
$211
Braintree Laboratories, Inc.
$181
Boehringer Ingelheim Pharmaceuticals, Inc.
$172
Boston Scientific Corporation
$159
IRONWOOD PHARMACEUTICALS, INC
$150
Shire North American Group Inc
$146
Synergy Pharmaceuticals Inc
$119
Lilly USA, LLC
$111
Regeneron Healthcare Solutions, Inc.
$104
VIVUS LLC
$103
RedHill Biopharma Inc.
$90
Phathom Pharmaceuticals, Inc.
$77
Organon Llc
$67
Prometheus Laboratories Inc.
$62
Nestle HealthCare Nutrition Inc.
$61
Romark Laboratories, LC
$59
Sandoz Inc.
$32
NESTLE HEALTHCARE NUTRITION INC.
$31
Olympus America Inc.
$26
BOSTON SCIENTIFIC CORPORATION
$26
FUJIFILM Healthcare Americas Corporation
$25
Concordia Pharmaceuticals Inc.
$24
Ambu Inc.
$24
Exact Sciences Corporation
$22
AIMMUNE THERAPEUTICS, INC.
$21
Gilead Sciences, Inc.
$20
E.R. Squibb & Sons, L.L.C.
$19
Celltrion USA Inc.
$17
Top 3 companies account for 35.4% of all-time payments
Associated products mentioned in payments ›
AMITIZA · AMJEVITA · APRISO · AVSOLA · Alinia · Alinia Tablets 500mg 30 count bottle · Amitiza · CIMZIA · CLENPIQ · CREON · CYCLOSET · CYLTEZO · Cimzia · Cologuard Collection Kit · Creon · DIFICID · DUPIXENT · Donnatal · ENTYVIO · EVIS EXERA · Entyvio · FUJIFILM · GATTEX · GENERAL ENDOCHOICE · GENERAL - ENDOCHOICE · General - Hemostasis · HADLIMA · HUMIRA · HYRIMOZ · Humira · IBSRELA · INFLECTRA · INJECTAFER · LINZESS · Linzess · MOTEGRITY · NASCOBAL · OMVOH · PLENVU · PREPOPIK · QSYMIA · REBYOTA · REMICADE · RENFLEXIS · RINVOQ · SKYRIZI · STELARA · SUCRAID · SUFLAVE · SUPREP · SUPREP BOWEL PREP · SUTAB · Sucraid · TREMFYA · TRULANCE · Talicia · Trulance · UCERIS · UCERIS TABLETS · VEGZELMA · VELSIPITY · VIBERZI · VOQUEZNA · VOWST · XELJANZ · XIFAXAN · ZENPEP · ZEPOSIA · ZINPLAVA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a gastroenterology specialist in New York?
Compare gastroenterologists in the New York area by procedure volume, costs, and industry payment transparency.
Browse gastroenterologists nearby

Geographic Context

Gastroenterologists within 10 mi
1,250
Per 100K population
76.8
County median income
$104,553
Nearest hospital
LENOX HILL HOSPITAL
0.6 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Legnani is a mixed practice specialist, with above-average Medicare volume (top 1% in NY), with low-engagement industry engagement in the top 12% of NY peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Legnani experienced with vedolizumab infusion (entyvio)?
Based on Medicare claims data, Dr. Legnani performed 14,700 vedolizumab infusion (entyvio) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Legnani receive payments from pharmaceutical companies?
Yes. Dr. Legnani received a total of $24,570 from 46 companies across 1,517 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Legnani's costs compare to other gastroenterologists in New York?
Dr. Legnani's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Legnani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →